Vesiculobullous skin disease
MONDO:0006617Skin diseases characterized by local or general distributions of blisters. They are classified according to the site and mode of blister formation. Lesions can appear spontaneously or be precipitated by infection, trauma, or sunlight. Etiologies include immunologic and genetic factors. (From Scientific American Medicine, 1990)
Also known as: vesiculobullous skin disease, Sneddon Wilkinson disease, Sneddon-Wilkinson disease, skin diseases, vesicular, subcorneal pustular dermatoses, subcorneal pustular dermatosis, bullous dermatoses, bullous skin disease
193 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
MRNA shingles vaccine trial ends early – what we know
⭐️ VACCINE ⭐️ TerminatedThis study tested several experimental mRNA vaccines against shingles in healthy adults aged 50 to 85. The goal was to check safety and immune response compared to the current shingles vaccine, Shingrix. The trial was terminated early, so results are limited, but the data may hel…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control TerminatedThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug shows promise for blistering skin disease in extended trial
Disease control TerminatedThis study looks at the long-term safety of a drug called efgartigimod for adults with moderate-to-severe bullous pemphigoid, a condition that causes painful blisters. Participants who finished the main study can continue treatment for up to 48 weeks, with the option to pause and…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC